Press Release – BioMark Diagnostics Announces Expansion of its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships
Press Release – BioMark Diagnostics Announces Expansion of its Specialty Laboratory Services in Quebec to Accommodate Increased Demand from International Partnerships Expansion of BioMark brings advanced equipment and doubles capacity, accelerating commercialization of lung cancer assay Vancouver, British Columbia – (August 5, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a […]
Press Release – BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 – 2026
BioMark Diagnostics Highlights Fiscal Year 2025 Achievements and Sets Bold Strategic Milestones for 2025 – 2026 VANCOUVER, BC – (July 30, 2025) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today announced a summary of its fiscal year […]
Press Release – BioMark Diagnostics Announces Breakthrough Publication Reinforcing Leadership in AI-Powered Metabolomics for Oncology
Novel Graph Neural Network (N-GNN) Model Achieves Superior Accuracy in Early Lung Cancer Detection, Paving the Way for Enhanced Diagnostic Capabilities. Vancouver, British Columbia – (May 20, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leader in developing liquid biopsy tests for early cancer detection, today announced the publication of […]
BioMark Diagnostics Announces Landmark Publication Validating High Specificity and Accuracy of its Early-Stage Lung Cancer Test
Study Published in a special issue of International Journal of Molecular Sciences Confirms Test’s Ability to Distinguish Early Lung Cancer from Other Non-Cancerous Lung Diseases Vancouver, British Columbia – (May 12, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today […]
BioMark Diagnostics Announces Uplisting to OTCQB Venture Market
Milestone strengthens transparency and credibility as the Company advances commercialization of its metabolomics technology platform Vancouver, British Columbia – (May 8th, 2025) BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (OTCQB: BMKDF) (FSE: 20B), a leading developer of liquid biopsy tests for early cancer detection, is pleased to announce that its common shares have […]
BioMark Announces the Final Closing of Oversubscribed Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BioMark Announces the Final Closing of Oversubscribed Private Placement Vancouver, British Columbia – (March 31, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, today announced the […]
BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. BioMark Secures Financing for Initial Tranche to Advance Early-Detection Oncology Testing Platform Vancouver, British Columbia – (March 26, 2025) BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer detection, is […]
Remembering Mia Love: A Trailblazer’s Legacy and Biomark’s Fight Against Cancer
Personal Reflection: A Shared Journey of Loss and Hope My journey with BioMark Diagnostics is deeply personal. Two years ago, I lost my sister in the UK to glioblastoma (GBM), a journey that began with breast cancer that tragically metastasized to her brain. I flew to London, spending the last six weeks by her side, […]
BioMark Diagnostics Underscores Commitment to Rare DiseaseResearch on Rare Disease Day 2025
BioMark Diagnostics Underscores Commitment to Rare Disease Research on Rare Disease Day 2025 BioMark is pioneering liquid biopsy solutions for challenging conditions and championing equity in diagnosis Vancouver, British Columbia – (February 28, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF), a leading developer of liquid biopsy tests for early cancer […]
From Black Plastics to Biomarkers How Environmental Causes of Cancer Can Be Prevented
From Black Plastics to Biomarkers How Environmental Causes of Cancer Can Be Prevented Seemingly harmless environmental factors in our homes can contribute to cancer risk. What you can do about it? Learn about the dangers of toxic chemicals like flame retardants and PFASs found in common household items such as plastic utensils and non-stick pans. […]